Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens.
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Despite the development of novel antibiotics active against Gram-positive bacteria, vancomycin generally remains the first treatment, although rapidly achieving concentrations associated with maximal efficacy provides an unresolved challenge. The objective of this study was to conduct a population pharmacokinetic analysis of vancomycin in a large population of critically ill patients. This was a retrospective data collection of 206 adult septic critically ill patients who were administered vancomycin as a loading dose followed by continuous infusion. The concentration-versus-time data for vancomycin in serum was analyzed by a nonlinear mixed-effects modeling approach using NONMEM. Monte Carlo simulations were performed using the final covariate model. We found that the best population pharmacokinetic model consisted of a one-compartment linear model with combined proportional and additive residual unknown variability. The volume of distribution of vancomycin (1.5 liters/kg) was described by total body weight and clearance (4.6 liters/h) by 24-hour urinary creatinine clearance (CrCl), normalized to body surface area. Simulation data showed that a 35-mg/kg loading dose was necessary to rapidly achieve vancomycin concentrations of 20 mg/liter. Daily vancomycin requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m 2 would require at least 35 mg/kg per day by continuous infusion to maintain target concentrations. In conclusion, we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 2×
“A significant body of work now describes the importance of early and appropriate antibiotic therapy as the intervention likely to minimize therapeutic failure (10, 17, 18).”
BackgroundAPACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Self-citationComparison of Dopamine and Norepinephrine in the Treatment of Shock
De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907118 · Cited by 1,940 · cited 1×
“The morbidity and mortality rates for sepsis and septic shock remain unacceptably high, with septic shock still associated with a 35 to 65% in-hospital mortality rate (5, 9).”
BackgroundSelf-citationInadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805 · cited 1×
“A significant body of work now describes the importance of early and appropriate antibiotic therapy as the intervention likely to minimize therapeutic failure (10, 17, 18).”
BackgroundRybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795 · cited 2×
“The aim of this regimen was to provide serum drug concentrations between 20 and 30 mg/liter (28).”
BackgroundMethodAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Consensus supports the view that the pharmacokinetic-pharmacodynamic parameter best correlated with the efficacy of vancomycin is the AUC0–24-to-MIC (AUC0–24/ MIC) ratio (8, 11, 29).”
BackgroundPharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862 · cited 1×
“Augmented renal clearance is common in hyperdynamic critically ill patients and may increase the risk for subtherapeutic vancomycin exposure (27, 31).”
BackgroundSelf-citation
Research works printed but not linked: 1
- BealS. L. SheinerL. B.. 1998. NONMEM user guides (I-VIII). University of California at San Francisco, San Francisco, CA.
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationKalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationRybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
“Loading doses of 25 to 35 mg/kg will require infusion times of at least 2 to 3 hours.(99) After administration of the loading dose, the initiation of the maintenance dose should occur at the next dosing interval (eg, an interval of every 6 hours indicates initiating the maintenance dose 6 hours after the start of the…”
BackgroundRoberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
“Critically ill patients have altered volumes of distribution for antibiotics [19, 20], and, unlike other patient groups, need larger initial doses to rapidly achieve therapeutic concentrations [21].”
BackgroundSelf-citationRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationvan Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Therapeutic drug monitoring of antimicrobials
Roberts, J. A., Norris, R., Paterson, D. L., & Martin, J. H. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04080.x · Cited by 316
Self-citationOptimizing the Clinical Use of Vancomycin
Álvarez, R., López Cortés, L. E., Molina, J., Cisneros, J. M., & Pachón, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03147-14 · Cited by 258
“The largest PK study on CoI of vancomycin showed that dosages need to be individualized according to the actual body weight (ABW) and creatinine clearance (CrCl) of the patient (44).”
BackgroundReview of vancomycin-induced renal toxicity: an update
Bamgbola, O. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816638223 · Cited by 239
Clinical implications of antibiotic pharmacokinetic principles in the critically ill
Udy, A. A., Roberts, J. A., & Lipman, J. (2013) · Intensive Care Medicine · doi:10.1007/s00134-013-3088-4 · Cited by 234
“Practical Tip: Clinicians should consider use of higher initial doses of aminoglycosides [94], betalactams [99], glycopeptides [84], tigecycline [90] and colistin [100] in septic, critically ill patients.”
BackgroundMethodSelf-citationThe Whole Price of Vancomycin: Toxicities, Troughs, and Time
Jeffres, M. N. (2017) · Drugs · doi:10.1007/s40265-017-0764-7 · Cited by 191
Kalil, A. C., Van Schooneveld, T. C., Fey, P. D., & Rupp, M. E. (2014) · JAMA · doi:10.1001/jama.2014.6364 · Cited by 172
Tängdén, T., Martin, V., Felton, T., Nielsen, E. I., Marchand, S., Brüggemann, R. J. M., Bulitta, J. B., Bassetti, M., Theuretzbacher, U., Tsuji, B. T., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4780-6 · Cited by 162
Self-citationBroeker, A., Nardecchia, M., Klinker, K. P., Derendorf, H., Day, R. O., Marriott, D. J. E., Carland, J. E., STOCKER, S. L., & Wicha, S. G. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.02.029 · Cited by 144
Alobaid, A. S., Hites, M., Lipman, J., Taccone, F. S., & Roberts, J. A. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.01.009 · Cited by 131
Self-citationZelenitsky, S. A., Rubinstein, E., Ariano, R. E., Iacovides, H., Dodek, P., Mirzanejad, Y., & Kumar, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.015 · Cited by 116
Shekar, K., Roberts, J. A., Welch, S. A., Buscher, H., Rudham, S., Burrows, F. S., Ghassabian, S., Wallis, S. C., Levkovich, B., Pellegrino, V., et al. (2012) · BMC Anesthesiology · doi:10.1186/1471-2253-12-29 · Cited by 124
“In critically ill patients not receiving ECMO, numerous PK studies have demonstrated highly significant changes to drug exposure through interactions between the patient, pathology and the drug [8-11].”
BackgroundSelf-citationVancomycin-Associated Nephrotoxicity in the Critically Ill
Hanrahan, T. P., Harlow, G., HUTCHINSON, J. H., Dulhunty, J. M., Lipman, J., Whitehouse, T., & Roberts, J. A. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000514 · Cited by 111
Self-citationBlot, S. I., Koulenti, D., Akova, M., Bassetti, M., Waele, J. J. D., Dimοpoulos, G., Kaukonen, K., Martin, C., Montravers, P., Rello, J., et al. (2014) · Critical Care · doi:10.1186/cc13874 · Cited by 108
“The above-mentioned conditions call for an altered dosing approach in critically ill patients compared with mild-to-moderately ill patients [12-14].”
BackgroundSelf-citationWong, G. Y. M., Sime, F. B., Lipman, J., & Roberts, J. A. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-288 · Cited by 124
“There is extensive evidence of sub-therapeutic exposure from standard doses across different antibiotic classes including beta-lactams [6,7], aminoglycosides [8], glycopeptides [9], fluoroquinolones [10], and oxazolidinones [11].”
BackgroundSelf-citationDonadello, K., Roberts, J. A., Cristallini, S., Beumier, M., Shekar, K., Jacobs, F., Belhaj, A., Vincent, J., Backer, D. D., & Taccone, F. S. (2014) · Critical Care · doi:10.1186/s13054-014-0632-8 · Cited by 103
“Doses were not changed during the first 24 h of therapy; afterwards, the daily drug regimen was adapted using a specific approach, as previously published [16-18]: if the serum vancomycin concentration was <20 μg/mL (considered insufficient), an additional dose of 500 to 1,000 mg was given followed by an increase in t…”
BackgroundMethodSelf-citationMonteiro, J., Hahn, S. R., Gonçalves, J., & Fresco, P. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.420 · Cited by 96
Jamal, J.-A., Economou, C. J. P., Lipman, J., & Roberts, J. A. (2012) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32835685ad · Cited by 96
“A larger loading dose subsequently followed by a large total maintenance dose such as that previously shown necessary for critically ill patients with conserved organ function is required [36].”
BackgroundSelf-citationColin, P. J., Allegaert, K., Thomson, A. H., Touw, D. J., Dolton, M. J., de Hoog, M., Roberts, J. A., Adane, E. D., Yamamoto, M., Buelga, D. S., et al. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0727-5 · Cited by 106
Self-citationUster, D. W., STOCKER, S. L., Carland, J. E., Brett, J., Marriott, D. J. E., Day, R. O., & Wicha, S. G. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2065 · Cited by 108
“5 L/kg, one third of the value in patients with sepsis, whereas the clearance is comparable.(16,20) In contrast, the clearance of vancomycin determined in trauma patients is significantly lower than in extremely obese and more similar to the clearance in critically ill patients undergoing heart surgery.”
BackgroundAn Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults
Aljutayli, A., Marsot, A., & Nekka, F. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00866-2 · Cited by 85
Roberts, J. A., Taccone, F. S., & Lipman, J. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-4032-6 · Cited by 100
“vancomycin 30 mg/kg [15]) are required to rapidly achieve therapeutic concentrations.”
BackgroundSelf-citationβ-lactam Therapeutic Drug Management in the PICU*
Cies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002817 · Cited by 95
Udy, A. A., Roberts, J. A., Lipman, J., & Blot, S. I. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.019 · Cited by 83
Self-citationParker, S. L., Lipman, J., Koulenti, D., Dimοpoulos, G., & Roberts, J. A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.05.018 · Cited by 75
Self-citationStrategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)
Bretonnière, C., Léone, M., Milési, C., Allaouchiche, B., Armand-Lefèvre, L., Baldési, O., Bouadma, L., Decré, D., Figueiredo, S., Gauzit, R., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3853-7 · Cited by 80
“lowed by continuous infusion of 35 mg/kg to maintain this target concentration [77].”
Ocampos-Martinez, E., Penaccini, L., Scolletta, S., Abdelhadii, A., Devigili, A., Cianferoni, S., Backer, D. D., Jacobs, F., COTTON, F. J., Vincent, J., et al. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.12.008 · Cited by 62
Self-citationGuo, T., van Hest, R. M., Roggeveen, L. F., Fleuren, L. M., Thoral, P., Bosman, R. J., van der Voort, P. H. J., Girbes, A. R. J., Mathôt, R. A. A., & Elbers, P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02543-18 · Cited by 64
“(21) was the only model complying with our criterion for validity: concentration-time data could be accurately predicted with both mean and median values of prediction error (PE) lower than 20% for the patients from the two hospitals.”
BackgroundMethodInfluentialRight Dose, Right Now: Customized Drug Dosing in the Critically Ill
Roberts, J. A., Kumar, A., & Lipman, J. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002210 · Cited by 70
Self-citationFraser, J. F., Shekar, K., Diab, S., Dunster, K. R., Foley, S. R., McDonald, C. I., Passmore, M. R., Gabriela, S., Roberts, J. A., Platts, D. G., et al. (2012) · ISBT Science Series · doi:10.1111/j.1751-2824.2012.01560.x · Cited by 67
Self-citationAntimicrobial stewardship: Time for change
Bowen, M. (2013) · Equine Veterinary Journal · doi:10.1111/evj.12041 · Cited by 58
Baptista, J. P., Roberts, J. A., Sousa, E., Freitas, R., Deveza, N., & Pimentel, J. (2014) · Critical Care · doi:10.1186/s13054-014-0654-2 · Cited by 58
“conducted a population pharmacokinetic analysis of vancomycin CI in a large cohort of critically ill patients, using a Monte Carlo dose simulation for different total body weight, for different creatinine clearances and for different weight-based dosing vancomycin CI regimens [35].”
BackgroundMethodSelf-citationUdy, A. A., Covajes, C., Taccone, F. S., Jacobs, F., Vincent, J., Lipman, J., & Roberts, J. A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.01.018 · Cited by 56
“For the treatment of MRSA infection, current guidelines recommend trough serum concentrations of 15–20 mg/L [12], with recent data highlighting the need for more aggressive dosing to achieve such targets [14].”
BackgroundResultSelf-citationA new regimen for continuous infusion of vancomycin during continuous renal replacement therapy
Beumier, M., Roberts, J. A., Kabtouri, H., Hites, M., COTTON, F. J., Wolff, F., Lipman, J., Jacobs, F., Vincent, J., & Taccone, F. S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt261 · Cited by 54
Self-citationTaylor, Z. L., Poweleit, E. A., Paice, K. M., Somers, K. M., Pavia, K. E., Vinks, A. A. T. M. M., Punt, N. C., Mizuno, T., & Girdwood, S. T. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13056 · Cited by 66
“In the case of Roberts et al., 66 CLcrN is normalized to 100 mL/min/1.73 m 2 , thus the reference patient has a CLcrN of 100 mL/min/1.73 m 2 and has a vancomycin CL of 4.58 L/h.”
BackgroundMethodInfluentialPrediction of vancomycin dose on high-dimensional data using machine learning techniques
Huang, X., Yu, Z. Y., Wei, X., Shi, J., Wang, Y., Wang, Z., Chen, J., Bu, S., Li, L., Gao, F., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1911642 · Cited by 56
“The most widely used index of renal function was the Cockcroft–Gault equation, which used age, weight, SCr, and gender to estimate CrCl [25].”
BackgroundMethodShekar, K., Roberts, J. A., Smith, M. T., Fung, Y. L., & Fraser, J. F. (2013) · BMC Anesthesiology · doi:10.1186/1471-2253-13-7 · Cited by 54
“Optimal antibiotic therapy in these patients is a balance between potency and exposure [12,28-31].”
BackgroundSelf-citationNew Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients
Cristallini, S., Hites, M., Kabtouri, H., Roberts, J. A., Beumier, M., COTTON, F. J., Lipman, J., Jacobs, F., Vincent, J., Créteur, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00330-16 · Cited by 52
“(8), using a population PK analysis, suggested that a vancomycin loading dose of 35 mg/kg, followed by daily doses adjusted to creatinine clearance (CrCL, ranging from 7 to 45 mg/kg/day), would rapidly achieve adequate drug concentrations in critically ill patients.”
MethodSelf-citationLi, J., Udy, A. A., Kirkpatrick, C. M. J., Lipman, J., & Roberts, J. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.08.017 · Cited by 51
Self-citationAcute bacterial skin and skin structure infections in internal medicine wards: old and new drugs
Falcone, M., Concia, E., Giusti, M., Mazzone, A., Santini, C., Stefani, S., & Violi, F. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1450-6 · Cited by 54
A Machine Learning Approach to Predict Interdose Vancomycin Exposure
Bououda, M., Uster, D. W., Sidorov, E., Labriffe, M., Marquet, P., Wicha, S. G., & Woillard, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03252-8 · Cited by 47
“Briefly, simulations have been performed from 6 POPPK models from heterogeneous populations including extremely obese [7], critically ill [8], hospitalized [9], and those with sepsis [10], trauma [11] and post-heart surgery [12].”
MethodThe ZEPHyR study: A randomized comparison of linezolid and vancomycin for MRSA pneumonia
Chavanet, P. (2013) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2013.09.011 · Cited by 47
Preparing and administering injectable antibiotics: How to avoid playing God
Longuet, P., Lecapitaine, A., Cassard, B., Batista, R., Gauzit, R., Lesprit, P., Haddad, R., Vanjak, D., & Diamantis, S. (2016) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2016.01.010 · Cited by 47
Management of Antimicrobial Use in the Intensive Care Unit
Álvarez-Lerma, F., & Grau, S. (2012) · Drugs · doi:10.2165/11599520-000000000-00000 · Cited by 52
ter Heine, R., Keizer, R. J., van Steeg, K., Smolders, E. J., van Luin, M., Derijks, H. J., de Jager, C. P. C., Frenzel, T., & Brüggemann, R. J. M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14360 · Cited by 46
“It was concluded that, on a population level, the model by Roberts et al.(20) performed satisfactorily.”
BackgroundMethodResultInfluentialCunio, C., Uster, D. W., Carland, J. E., Buscher, H., Liu, Z., Brett, J., Stefani, M., Jones, G. R. D., Day, R. O., Wicha, S. G., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.005 · Cited by 54
Subtleties in practical application of prolonged infusion of β-lactam antibiotics.
De Waele, J. J., Lipman, J., Carlier, M., & Roberts, J. A. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.01.007 · Cited by 44
Self-citationMavros, M. N., Tansarli, G. S., Vardakas, K. Z., Rafailidis, P. I., Karageorgopoulos, D. E., & Falagas, M. E. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.07.023 · Cited by 45
Aloy, B., Launay‐Vacher, V., Bleibtreu, A., Bortolotti, P., Faure, E., Filali, A., Gauzit, R., Gilbert, M., Lesprit, P., Mahieu, R., et al. (2019) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2019.06.010 · Cited by 50
Lipman, J., Udy, A. A., & Roberts, J. A. (2011) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1103900602 · Cited by 46
Self-citationLonsdale, D. O., Udy, A. A., Roberts, J. A., & Lipman, J. (2012) · Journal of neurosurgery · doi:10.3171/2012.10.jns12883 · Cited by 49
Self-citationRoger, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.12.007 · Cited by 57
Mangin, O., Urien, S., Mainardi, J., Fagon, J.-Y., & Faisy, C. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0164-z · Cited by 46
Antimicrobial Dosing in Acute Renal Replacement
Fissell, W. H. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.10.004 · Cited by 42
“The free fraction of many drugs – phenytoin, digoxin, and others is increased in renal failure, even though the volume of distribution for total drug may increase due to movement of unbound drug into interstitial or total body water (34, 35).”
BackgroundDiamantis, S., Dawudi, Y., Cassard, B., Longuet, P., Lesprit, P., & Gauzit, R. (2020) · Infectious Diseases Now · doi:10.1016/j.medmal.2020.10.019 · Cited by 48
Ampe, E., Delaere, B., Hecq, J., Tulkens, P. M., & Glupczynski, Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.01.009 · Cited by 42
Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications
Pea, F. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0572-y · Cited by 41
“This has been demonstrated especially for the aminoglycosides [93–97] and for the glycopeptides [98, 99].”
BackgroundReview of Continuous-Infusion Vancomycin
DiMondi, V. P., & Rafferty, K. D. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r420 · Cited by 45
Medellín‐Garibay, S. E., Romano‐Moreno, S., Prado, P. T., Álvaro, N. R., Rueda-Naharro, A., Blasco-Navalpotro, M. Á., García, B., & Barcia, E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01249-17 · Cited by 38
“Considering that V is higher than that reported for non-critically ill patients but lower than that for septic patients (19, 27), categorization according to disease or”
BackgroundResultBlassmann, U., Hope, W. W., Roehr, A. C., Frey, O. R., Vetter‐Kerkhoff, C., Thon, N., Briegel, J., & Huge, V. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky543 · Cited by 39
Zelenitsky, S. A., Ariano, R. E., McCrae, M. L., & Vercaigne, L. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis458 · Cited by 37
The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion
Waineo, M. F., Kuhn, T. C., & Brown, D. L. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12270 · Cited by 36
“They projected that to reliably achieve a Css of 20–30 mg/L in septic patients with normal renal function, one would need to administer a loading dose of 35 mg/kg (actual body weight) and a daily infusion of 25 mg/ kg.(27) Baptista et al.”
BackgroundMethodInfluentialFalcone, M., Russo, A., & Venditti, M. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.02.012 · Cited by 41
Escobar, L., Andresen, M., Downey, P., Gai, M. N., Regueira, T., Bórquez, T., Lipman, J., & Roberts, J. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.03.009 · Cited by 35
Self-citationEconomou, C. J. P., Kielstein, J. T., Czock, D., Xie, J., Field, J., Richards, B., Tallott, M., Visser, A., König, C., Hafer, C., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.03.001 · Cited by 35
Self-citationAdnan, S., Paterson, D. L., Lipman, J., Kumar, S., Li, J., Rudd, M., & Roberts, J. A. (2012) · Surgical Infections · doi:10.1089/sur.2011.046 · Cited by 36
“Dosing guidance from the product insert is obtained from well-controlled clinical trials in patients without significant pathologies and so does not account for the complex pathophysiology of these patients [60,61].”
Self-citationKim, J., Walker, S. A. N., Iaboni, D. C., Walker, S. E., Elligsen, M., Dunn, M., Allen, V. G., & Simor, A. E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01718-13 · Cited by 35
Waele, J. J. D., Danneels, I., Depuydt, P. O., Decruyenaere, J. M. A., Bourgeois, M., & Hoste, E. A. J. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.12.015 · Cited by 34
“Overall, a common recommendation is that critically ill patients without kidney dysfunction require higher daily doses to reach adequate concentrations [6,7].”
BackgroundInfluentialOvercoming barriers to optimal drug dosing during ECMO in critically ill adult patients
Cheng, V., Abdul-Aziz, M. H., Roberts, J. A., & Shekar, K. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1563596 · Cited by 37
Self-citationDinu, V. T., Lu, Y., Weston, N., Lithgo, R. M., Coupe, H., Channell, G. A., Adams, G. G., Torcello‐Gómez, A., Sabater, C., Mackie, A. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57776-3 · Cited by 39
Non-flushing of IV administration sets: an under-recognised under-dosing risk
Cooper, D. M., Rassam, T., & Mellor, A. J. (2018) · British Journal of Nursing · doi:10.12968/bjon.2018.27.14.s4 · Cited by 33
Roggeveen, L. F., Fleuren, L. M., Guo, T., Thoral, P., de Grooth, H., Swart, E. L., Klausch, T. L. T., van der Voort, P. H. J., Girbes, A. R. J., Bosman, R. J., et al. (2019) · Trials · doi:10.1186/s13063-019-3911-5 · Cited by 38
The use and risks of antibiotics in critically ill patients
Denny, K. J., Cotta, M. O., Parker, S. L., Roberts, J. A., & Lipman, J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164690 · Cited by 33
“Previous work has shown that the volume of distribution can be twofold greater in the critically ill population for hydrophilic antibiotics such as the aminoglycosides,[116] β-lactams [117,118] and glycopeptides.[29] Therefore, higher initial doses of these agents are most likely needed to rapidly achieve target conce…”
BackgroundSelf-citationBrink, A. J. (2012) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e3283578968 · Cited by 31
Appropriate Antibiotic Dosage Levels in the Treatment of Severe Sepsis and Septic Shock
Taccone, F. S., Hites, M., Beumier, M., Scolletta, S., & Jacobs, F. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0203-y · Cited by 32
Self-citationLi, X., Wu, Y., Sun, S., Zhao, Z., & Wang, Q. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.08.012 · Cited by 32
Heffernan, A. J., Germano, A. J. M. M. E. T., Sime, F. B., Roberts, J. A., & Kimura, E. M. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02694-1 · Cited by 30
Self-citationVu, D. H., Nguyen, D. A., Delattre, I., Ho, T. T., Hong, G.-R., Pham, H. N., Co, D. X., Tran, N. T., Nguyen, G. B., Françoise Van Bambeke, A., et al. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.018 · Cited by 30
Kovačević, T., Miljković, B., Kovačević, P., Dragić, S., Momčićević, D., Avram, S., Jovanović, M., & Vučićević, K. M. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.10.012 · Cited by 28
El catéter periférico: el gran olvidado de la infección nosocomial
Capdevila, J. A. (2013) · Revista española de quimioterapia. Suplemento · Cited by 57
Fornasaro, S., Cialla‐May, D., Sergo, V., & Bonifacio, A. (2022) · Chemosensors · doi:10.3390/chemosensors10040128 · Cited by 27
“There is extensive evidence of sub-therapeutic exposure in critically ill patients from standard doses across different antimicrobials including aminoglycosides [4], beta-lactams [5], fluoroquinolones [6], glycopeptides [7], and azoles [8].”
BackgroundDose modulation: A new concept of antibiotic therapy in the critically ill patient?
Gonçalves-Pereira, J., & Paiva, J.-A. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2012.11.018 · Cited by 27
“Therapeutic drug monitoring [16] and population PK [8,21] has been proposed to accomplish it.”
BackgroundContinuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients
Hong, L. T., Goolsby, T. A., Sherman, D. S., Mueller, S. W., Reynolds, P., Cava, L. F., Neumann, R. T., & Kiser, T. H. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2015.06.012 · Cited by 25
Jalusic, K. O., Hempel, G., Arnemann, P., Spiekermann, C., Kampmeier, T., Ertmer, C., Gastine, S., & Heßler, M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14657 · Cited by 24
Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence
Girand, H. L. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.3.198 · Cited by 24
Delattre, I., Hites, M., Laterre, P., Dugernier, T., Spapen, H. D., Wallemacq, P. E., Jacobs, F., & Taccone, F. S. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106113 · Cited by 24
Self-citationXiao, Q., Zhang, H., Wu, X., Qu, J., Qin, L., & Wang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835557 · Cited by 28
“A typical value for Vd was 155.4 L/h, which was 1.3–3.6 times higher than those reported in other literature (Roberts et al., 2011; Heffernan et al., 2019; Vu et al., 2019; Pongchaidecha et al., 2020).”
BackgroundMethodResultInfluentialDevelopment of acute kidney injury during continuous infusion of vancomycin in septic patients
Cianferoni, S., Devigili, A., Ocampos-Martinez, E., Penaccini, L., Scolletta, S., Abdelhadii, A., Backer, D. D., Beumier, M., Jacobs, F., Vincent, J., et al. (2013) · Infection · doi:10.1007/s15010-013-0460-9 · Cited by 26
Self-citationDeng, C., Liu, T., Wu, K., Wang, S., Li, L., Lu, H., Zhou, T., Cheng, D.-H., Zhong, X.-N., & Lu, W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12092 · Cited by 23
“The results of this study did not show a significant difference in prediction between peak and trough concentrations except for Roberts’ model.(32) They built a one-compartment model based on a retrospective data set.”
BackgroundAgema, B. C., Kocher, T., Öztürk, A. B., Giraud, E. L., van Erp, N. P., de Winter, B. C. M., Mathijssen, R. H. J., Koolen, S. L. W., Koch, B. C. P., & Sassen, S. D. T. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01425-9 · Cited by 22
Heus, A., Uster, D. W., Grootaert, V., Vermeulen, N., Somers, A., Veld, D. H. I. ‘., Wicha, S. G., & Cock, P. A. J. G. D. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106579 · Cited by 22
Antimicrobial Treatment of Febrile Neutropenia: Pharmacokinetic–Pharmacodynamic Considerations
Goulenok, T. M., & Fantin, B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0086-1 · Cited by 22
Conil, J., Georges, B., Breden, A., Ruiz, S., Cougot, P., Fourcade, O., & Saivin, S. (2014) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1404200203 · Cited by 21
Chen, A., Gupta, A., Huy, D., & Nazer, L. H. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1026 · Cited by 19
Metadata
- Authors
- Roberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Roberts, Jason A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-06
- Volume
- 55
- Issue
- 6
- Pages
- 2704-2709
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3101407
- OpenAlex
- W2161342563
- Semantic Scholar
- 6a21d1534090532b1e164a9fa3b5932d1c6a8db8
- Cited by
- 226
- References
- 35
- Citations by year
- 2026: 14 · 2025: 5 · 2024: 9 · 2023: 16 · 2022: 19 · 2021: 12 · 2020: 18 · 2019: 14 · 2018: 8 · 2017: 21 · 2016: 15 · 2015: 9 · 2014: 18 · 2013: 25 · 2012: 18
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- vancomycin, population pharmacokinetics, continuous infusion, critically ill patients, sepsis, loading dose, renal clearance, creatinine clearance, dose adjustment, target attainment, Gram-positive bacterial infections, Monte Carlo simulation
- MeSH terms
- Adult, Aged, Anti-Bacterial Agents, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Retrospective Studies, Vancomycin, Critical Illness, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.